颈动脉血运重建术式分层结局:估算肾小球滤过率<30及透析患者
基于血管质量倡议(VQI)2016至2023年数据,纳入eGFR<30 mL/min/1.73 m2或透析的颈动脉血运重建患者,按术式分为TCAR、tfCAS和CEA三组,采用逆概率加权比较围术期及5年结局。加权队列13,851例中,CEA较TCAR的SDM和MI发生比值更高,tfCAS较TCAR的SDM、卒中、死亡发生率均更高。CEA与TCAR卒中和死亡风险相似,作者认为两者均为合理选择,TCAR在MI风险增高患者中可能更优。
要点
- CEA较TCAR围术期SDM(2.8% vs 3.6%;aOR 1.27;95%CI 1.00-1.61;P=.049)和MI(0.7% vs 1.5%;aOR 2.00;95%CI 1.31-3.05;P=.001)比值更高。
- tfCAS较TCAR的SDM(2.8% vs 5.8%)、卒中(1.2% vs 2.6%)和死亡(0.9% vs 2.4%)发生率均更高。
- TCAR与CEA的5年生存相似(eGFR<30:75.1% vs 74.2%;aHR 1.06;P=.3),tfCAS较低(75.1% vs 70.4%;aHR 1.44;P<.001)。
核心结论
- CEA与TCAR的卒中和死亡发生比值相似,作者认为两者均为该人群的合理选择;但TCAR在MI风险增高的患者中可能更优。
- 经症状状态加权后,tfCAS患者的结局更差。
- 作者指出,尽管eGFR降低患者的结局差于健康人群,本分析显示多数患者存活时间足以从所有血运重建术式带来的潜在卒中风险降低中获益。
研究设计与样本
- 基于血管质量倡议(VQI)的队列研究,纳入2016至2023年接受TCAR、tfCAS或CEA且eGFR<30 mL/min/1.73 m2或透析的患者。
- 按术式分组,并针对仅透析患者及按症状状态进行额外分析。
- 采用逆概率治疗加权,调整人口学、合并症和术前症状;加权队列共13,851例,其中透析患者2506例。
- 加权队列中TCAR 3639例(透析704例)、tfCAS 1975例(透析393例)、CEA 8237例(透析1409例)。
- 使用χ2检验和多变量logistic回归评估术式与围术期结局的关联,采用Kaplan-Meier和加权Cox回归评估5年生存。
主要发现
- 与TCAR相比,CEA的SDM比值更高(2.8% vs 3.6%;aOR 1.27;95%CI 1.00-1.61;P=.049),MI比值更高(0.7% vs 1.5%;aOR 2.00;95%CI 1.31-3.05;P=.001)。
- 与TCAR相比,tfCAS的SDM(2.8% vs 5.8%)、卒中(1.2% vs 2.6%)和死亡(0.9% vs 2.4%)发生率均更高。
- 无症状患者中,CEA的MI比值更高(0.7% vs 1.3%;aOR 1.85;95%CI 1.15-2.97;P=.011),颅神经损伤比值更高(0.3% vs 1.9%;aOR 7.23;95%CI 3.28-15.9;P<.001)。
- 无症状tfCAS患者死亡和卒中/死亡比值更高;有症状CEA患者卒中、死亡或卒中/死亡无差异;有症状tfCAS患者死亡、卒中、MI、卒中/死亡和SDM比值更高。
- 5年生存TCAR与CEA相似(eGFR<30:75.1% vs 74.2%;aHR 1.06;P=.3),tfCAS较低(eGFR<30:75.1% vs 70.4%;aHR 1.44;P<.001)。
临床怎么用
- 作者认为,在该eGFR<30或透析人群中CEA与TCAR均为合理选择,TCAR在MI风险增高的患者中可能更优。
- 作者指出,tfCAS经症状状态加权后结局更差。
- 作者认为,多数患者存活时间足以从所有血运重建术式带来的潜在卒中风险降低中获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Renal failure is a predictor of adverse outcomes in carotid revascularization. There has been debate regarding the benefit of revascularization in patients with severe chronic kidney disease or on dialysis. METHODS: Patients in the Vascular Quality Initiative undergoing transcarotid artery revascularization (TCAR), transfemoral carotid artery stenting (tfCAS), or CEA between 2016 and 2023 with an estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73 m2 or on dialysis were included. Patients were divided into cohorts based on procedure. Additional analyses were performed for patients on dialysis only and by symptomatology. Primary outcomes were perioperative stroke/death/myocardial infarction (MI) (SDM). Secondary outcomes included perioperative death, stroke, MI, cranial nerve injury, and stroke/death. Inverse probability of treatment weighting was performed based on treatment assignment to TCAR, tfCAS, and CEA patients and adjusted for demographics, comorbidities, and preoperative symptoms. The χ2 test and multivariable logistic regression analysis were used to evaluate the association of procedure with perioperative outcomes in the weighted cohort. Five-year survival was evaluated using Kaplan-Meier and weighted Cox regression. RESULTS: In the weighted cohort, 13,851 patients with an eGFR of <30 (2506 on dialysis) underwent TCAR (3639; 704 on dialysis), tfCAS (1975; 393 on dialysis), or CEA (8237; 1409 on dialysis) during the study period. Compared with TCAR, CEA had higher odds of SDM (2.8% vs 3.6%; adjusted odds ratio [aOR], 1.27; 95% confidence interval [CI], 1.00-1.61; P = .049), and MI (0.7% vs 1.5%; aOR, 2.00; 95% CI, 1.31-3.05; P = .001). Compared with TCAR, rates of SDM (2.8% vs 5.8%), stroke (1.2% vs 2.6%), and death (0.9% vs 2.4%) were all higher for tfCAS. In asymptomatic patients CEA patients had higher odds of MI (0.7% vs 1.3%; aOR, 1.85; 95% CI, 1.15-2.97; P = .011) and cranial nerve injury (0.3% vs 1.9%; aOR, 7.23; 95% CI, 3.28-15.9; P < .001). Like in the primary analysis, asymptomatic tfCAS patients demonstrated higher odds of death and stroke/death. Symptomatic CEA patients demonstrated no difference in stroke, death, or stroke/death. Although tfCAS patients demonstrated higher odds of death, stroke, MI, stroke/death, and SDM. In both groups, the 5-year survival was similar for TCAR and CEA (eGFR <30, 75.1% vs 74.2%; aHR, 1.06; P = .3) and lower for tfCAS (eGFR <30, 75.1% vs 70.4%; aHR, 1.44; P < .001). CONCLUSIONS: CEA and TCAR had similar odds of stroke and death and are both a reasonable choice in this population; however, TCAR may be better in patients with an increased risk of MI. Additionally, tfCAS patients were more likely to have worse outcomes after weighting for symptom status. Finally, although patients with a reduced eGFR have worse outcomes than their healthy peers, this analysis shows that the majority of patients survive long enough to benefit from the potential stroke risk reduction provided by all revascularization procedures.
引用
- Caron E, Yadavalli SD, Manchella M, et al. Outcomes of carotid revascularization stratified by procedure in patients with an estimated glomerular filtration rate of <30 and dialysis patients. J Vasc Surg. 2024. PMID: 38906431. doi:10.1016/j.jvs.2024.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。